# CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

> **NCT06822881** · PHASE1 · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Systemic Sclerosis (SSc)

## Interventions

- **DRUG:** CAR-T Therapy

## Key facts

- **NCT ID:** NCT06822881
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06822881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06822881, "CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06822881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*